Wellington Partners: new €210 million life science fund
Munich — International law firm Clifford Chance has advised Wellington Partners on its successful fundraising for its fifth fund, Wellington Partners Life Science Fund V (WPLS‑V). The fund closed at €210 million, making it Wellington Partners’ largest life science fund to date.
Wellington Partners is a leading European venture capital firm investing in early and growth stage life science companies. The funds from WPLS V will be spent on a portfolio of approximately 15 to 20 companies that are active in biotechnology or are developing new therapies and medical devices. Selected investments in diagnostics and digital health are also part of the investment strategy. The geographical focus is on Europe, in particular the German-speaking region. In addition, isolated investments in North America or Asia are also being considered.
WPLS‑V gained many new well-known investors such as KfW Capital, Talanx and the U.S. UTIMCO, the University of Texas/Texas A&M Investment Company. Existing investors such as the European Investment Fund and the European Investment Bank also participated.
The advising Clifford Chance team was led by partner Sonya Pauls(photo, Corporate/Private Equity, Munich).
About Clifford Chance
Clifford Chance, one of the world’s leading law firms, is present for its clients with around 3,400 legal advisors in all major business centers around the world. — In Germany, Clifford Chance is represented by around 300 lawyers, auditors, tax advisors and solicitors in Düsseldorf, Frankfurt am Main and Munich.